{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:34:19Z","timestamp":1792467259285,"version":"4.5.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune thrombocytopenia (ITP) is characterized by reduced platelet count due to increased destruction and is categorized according to the time following diagnosis (newly diagnosed, persistent, chronic). First\u2010line corticosteroid therapy is associated with transient response, high relapse rates, and considerable toxicity. TAPER (NCT03524612) is a Phase II, prospective, single\u2010arm trial investigating whether eltrombopag can induce a sustained response off\u2010treatment (SRoT) in adult patients with ITP after first\u2010line corticosteroid failure. This study defines SRoT as an off\u2010treatment period wherein platelet count remains above 30\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L in the absence of bleeding or rescue therapy. The primary endpoint was the proportion of patients who achieved SRoT until Month 12, which was 30.5% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200932\/105;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.0001 testing hypothesis H1: proportion &gt;15%) following eltrombopag tapering and discontinuation, and median SRoT duration was ~8\u2009months until Month 12. Median platelet count increased within 1\u2009month of treatment and remained elevated until Month 12. Quality of life improved within 3\u2009months and was maintained. Headache (21%) was the most common adverse event. None of the 4 deaths reported were considered treatment\u2010related. In summary, ~one\u2010third of patients achieved SRoT until Month 12 following eltrombopag tapering and discontinuation. An ad\u2010hoc early\u2010use analysis, stratified by ITP duration at baseline, assessed initial hematologic responses and safety. Results suggest that eltrombopag has similar efficacy in newly diagnosed and later stages of ITP. In follow\u2010up until Month 24, a median SRoT duration of ~22\u2009months was observed (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920). The safety profile was comparable across analyses and ITP duration groups and aligned with its well\u2010established safety profile.\n                  <\/jats:p>","DOI":"10.1002\/ajh.27131","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:50:57Z","timestamp":1701165057000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Sustained response off\u2010treatment in eltrombopag\u2010treated adult patients with\n                    <scp>ITP<\/scp>\n                    who are refractory or relapsed after first\u2010line steroids: Primary, final, and ad\u2010hoc analyses of the Phase\n                    <scp>II TAPER<\/scp>\n                    trial"],"prefix":"10.1002","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-8292","authenticated-orcid":false,"given":"Nichola","family":"Cooper","sequence":"first","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation Imperial College London, Hammersmith Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010Oncology \u00d8stfold Hospital Trust, Kalnes  Gr\u00e5lum Norway"},{"name":"Department of Haematology, Oslo University Hospital, Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[{"name":"Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO) University Hospital Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1703-2175","authenticated-orcid":false,"given":"\u0130rfan","family":"Yava\u015fo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology Adnan Menderes University  Ayd\u0131n Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anait","family":"Melikyan","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Ya\u00f1ez","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Hematology\u2010Oncology Unit, Department of Internal Medicine, School of Medicine Universidad de La Frontera  Temuco Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Haenig","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Somenzi","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lee","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Clark","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical and Health Sciences University of Trieste  Trieste Italy"},{"name":"UCO Ematologia Azienda Sanitaria Universitaria Giuliano Isontina  Trieste Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25092"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"e_1_2_10_7_1","volume-title":"Prescribing Information","author":"Novartis Pharmaceuticals Corporation","year":"2021"},{"key":"e_1_2_10_8_1","volume-title":"Summary of Product Characteristics","author":"Novartis Europharm Limited","year":"2022"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13827"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17334"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010735"},{"issue":"23","key":"e_1_2_10_12_1","first-page":"2867","article-title":"Prolonged response after TPO\u2010RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet S","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2275-4"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26404"},{"key":"e_1_2_10_15_1","unstructured":"ClinicalTrials.gov.A study to assess the ability of eltrombopag to induce sustained remission in subjects with ITP (TAPER).https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03524612"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25348"}],"updated-by":[{"DOI":"10.1002\/ajh.27238","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000}}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T06:22:31Z","timestamp":1705904551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/ajh.27131"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27131","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"2022-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}